Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409510 | 0.89 | HRH3 (0.44) | HRH3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL12183728 | 0.88 | HRH3 (0.44) | HRH3GPR119MAPT | |
| SCHEMBL12183699 | 0.85 | GPR119 (0.48) | HRH3GPR119 | |
| SCHEMBL9936587 | 0.80 | GPR119 (0.40) | HRH3MEN1KMT2AGPR119MAPT | |
| SCHEMBL9936334 | 0.80 | GPR119 (0.40) | HRH3MEN1KMT2AGPR119MAPT | |
| SCHEMBL9936330 | 0.80 | GPR119 (0.40) | HRH3MEN1KMT2AGPR119MAPT | |
| SCHEMBL31235937 | 0.76 | GPR119 (0.63) | HRH3GPR119HDAC1HDAC2 | |
| SCHEMBL15035133 | 0.75 | GPR119 (0.46) | GPR119 | |
| SCHEMBL18706930 | 0.75 | NR1H2 (0.49) | HRH3GPR119HPGDSHDAC1HDAC2 | |
| SCHEMBL14244872 | 0.74 | GPR119 (0.58) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | HRH3 1146/4885MEN1 183/4885KMT2A 1317/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | HRH3 1146/4885MEN1 183/4885KMT2A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.